# Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis

> **NCT00802672** · PHASE3 · COMPLETED · sponsor: **Padagis LLC** · enrollment: 561 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** Ciclopirox Olamine Cream
- **DRUG:** Loprox Cream 0.77%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00802672
- **Lead sponsor:** Padagis LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 561 (ACTUAL)
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802672, "Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00802672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*